ACQUISITIONS (Details) (USD $)	3 Months Ended		9 Months Ended		3 Months Ended		9 Months Ended							3 Months Ended	9 Months Ended
	Dec. 29, 2012	Dec. 31, 2011	Dec. 29, 2012	Dec. 31, 2011	Dec. 29, 2012 Pall Corporation [Member]		Dec. 29, 2012 Pall Corporation [Member]		Dec. 31, 2011 Pall Corporation [Member]		Aug. 01, 2012 Pall Corporation [Member]	Dec. 29, 2012 Acquired Technology [Member] Pall Corporation [Member]	Dec. 29, 2012 Customer Relationships [Member] Pall Corporation [Member]	Dec. 29, 2012 Acquired Technology and Customer Relationships [Member] Pall Corporation [Member]	Dec. 29, 2012 Acquired Technology and Customer Relationships [Member] Pall Corporation [Member]	Dec. 29, 2012 Purchase Price Allocation Adjustments [Member] Pall Corporation [Member]
Business Acquisition [Line Items]
Business acquistion, cost of aquired entity											$ 535,100,000					$ 4,500,000
Business acqusition, post closing adjustmetns accrued					4,600,000
Business acquisition, additional anticipated payment											15,000,000
Face amount of debt											475,000,000
Asset class
Inventories					50,741,000		50,741,000									(1,700,000)
Property, plant and equipment					93,847,000		93,847,000									23,100,000
Intangible assets					188,500,000		188,500,000					61,000,000	127,500,000			(18,300,000)
Other assets/liabilities, net					320,000		320,000
Other assets																100,000
Other Liabilities																(2,000,000)
Goodwill					206,303,000		206,303,000									(700,000)
Fair value of net assets acquired					539,711,000		539,711,000
Estimated useful life														11 years
Amortization expense														3,700,000	7,100,000
Revenue since acquisition							83,500,000
Earnings since acquisition							8,000,000
Cost of goods sold	134,280,000	95,229,000	337,058,000	266,545,000	11,100,000
Business Acquisition, Pro Forma Information [Abstract]
Net sales							713,981,000		703,023,000
Net income							42,975,000		47,961,000
Basic earnigs per share (in dollars per share)							$ 0.84		$ 0.94
Diluted earnigs per share (in dollars per share)							$ 0.82		$ 0.93
Transaction costs					3,184,000	[1]	3,184,000	[1]	0	[1]
Amortization of inventory fair value adjustment					11,067,000	[2]	11,067,000	[2]	(11,067,000)	[2]
Amortization of acquired intangible assets					(5,712,000)	[3]	(5,712,000)	[3]	(12,852,000)	[3]
Interest expense incurred on acquisition financing					(3,173,000)	[4]	(3,173,000)	[4]	(7,137,000)	[4]
Selling, general and admin expenses					(3,513,000)	[5]	(3,513,000)	[5]	(7,905,000)	[5]
Amount of transaction prior to acquisition											$ 10,000,000

[1] Eliminated transactions costs as these non-recurring costs were incurred in the first and second quarters of FY13.

[2] Added additional expense in the period ended December 31, 2011 to reflect the inventory fair value adjustments which would have been amortized had the transaction been consummated on April 3, 2011 as the corresponding inventory would have been completely sold during the first two quarters of 2011. Also, deducted the actual inventory fair value adjustment recorded in the nine months ended December 29, 2012 to reflect the pro-forma consumption of inventory in 2011.

[3] Added additional amortization of the acquired whole blood intangible assets recognized at fair value in purchase accounting

[4] Added additional interest expense for the debt used to finance the acquisition.

[5] Additional investments in infrastructure costs to replicate certain support functions performed by division or corporate organizations of Pall that did not transfer in the acquisition. These costs are primarily related to information technology infrastructure and application costs, and personnel costs required to expand regional and corporate administrative and sales support functions. These costs are not intended to be representative of actual costs incurred by Pall Corporation, and represent Haemonetics' best estimate of future incremental costs on an annualized basis. Actual incremental investments may differ from these estimates